We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Blood Test Can Detect Predictive Biomarker for Cognitive Impairment and Dementia

By LabMedica International staff writers
Posted on 20 Dec 2022

Ergothioneine (ET) is a unique diet-derived compound discovered more than 100 years ago by Charles Tanret. More...

However, it was only in 2005 when scientists discovered a transporter specific for ET that facilitates the uptake and accumulation of ET in the body. Now, a new study has revealed that low levels of ET in blood plasma may predict an increased risk of cognitive impairment and dementia, suggesting possible therapeutic or early screening measures for cognitive impairment and dementia in the elderly.

A team of researchers from the National University of Singapore (NUS, Singapore) demonstrated that ET is avidly retained in the human body following oral supplementation, and in preclinical models, ET is transported to almost all organs, although higher levels can be found in specific cells and tissues such as the blood cells, eyes, liver, lungs, and even the brain. Their earlier work demonstrated the potent antioxidant properties of ET and later its ability to protect cells from a range of different forms of stress and toxins. As its main dietary source is in mushrooms, it was found that increasing consumption of mushrooms such as golden, oyster, shiitake and white button mushrooms is associated with a reduced risk of mild cognitive impairment in elderly Singaporeans. Low ET levels are also associated with a number of other age-related diseases such as frailty, cardiovascular disease and macular degeneration, so ET may have a more general role in maintaining health.

An earlier study by the research team in 2016 showed lower ET levels in blood plasma among participants with mild cognitive impairment. This was verified in a much larger group of cognitively impaired participants with and without dementia. However, evidence of whether a low level of ET in blood plasma can predict the progression of cognitive impairment and dementia was unknown. The most recent study by the NUS research team addresses these gaps in ET research by demonstrating the potential of ET as a predictive biomarker for cognitive impairment and dementia in elderly Singaporeans.

In the latest study, the research team recruited 470 elderly patients and followed them for up to five years. The researchers measured ET levels in the blood plasma of the participants and followed their cognitive and functional abilities at different time points. They then examined the link between low ET levels and the risk of cognitive and functional decline over time. The researchers showed that participants with lower levels of ET displayed poorer cognitive performance at the start of the study and an accelerated rate of decline in cognitive and functional abilities over the follow-up period.

The team also observed structural changes in the brain seen from MRI (magnetic resonance imaging) scans of the participants, which suggested that the association between a low ET level in blood and cognitive decline was due to underlying disease pathology. These structural changes, including reduced cortical thickness, lower hippocampus volume, and white matter hyperintensities, are characteristic of neurodegenerative disease. Based on this study, which showed that plasma ET levels in the blood can be a predictive biomarker for the risk of cognitive and functional decline, the research team hopes to gather further evidence of ET’s preventive and therapeutic potential through a double-blinded placebo-controlled clinical trial.

"Before this study, there was little evidence that ET levels in the blood can predict the risk of developing cognitive issues. The current study is significant because it measured the ET levels of elderly participants before developing dementia. Our findings demonstrate that if your ET levels are low, your risk of developing cognitive problems increases,” said Professor Barry Halliwell from the Department of Biochemistry under the NUS Yong Loo Lin School of Medicine who led the research team. “This points to the possibility of using a simple blood test to detect ET levels for early screening in the elderly to identify those who may have higher risk of cognitive decline.”

Related Links:
NUS


New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Test Reader
DIA5000
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.